Erythropoietin for stroke treatment: dead or alive?

Endothelial progenitor cell (EPC) mobilization from the bone marrow was considered to improve outcome after ischemic stroke. Erythropoietin (EPO) might be a potential candidate stroke drug that increases the number of circulating EPCs. In the previous issue of Critical Care, Yip and colleagues inves...

Descripción completa

Detalles Bibliográficos
Autores principales: Minnerup, Jens, Wersching, Heike, Schäbitz, Wolf-Rüdiger
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3219325/
https://www.ncbi.nlm.nih.gov/pubmed/21418552
http://dx.doi.org/10.1186/cc10057
_version_ 1782216819566706688
author Minnerup, Jens
Wersching, Heike
Schäbitz, Wolf-Rüdiger
author_facet Minnerup, Jens
Wersching, Heike
Schäbitz, Wolf-Rüdiger
author_sort Minnerup, Jens
collection PubMed
description Endothelial progenitor cell (EPC) mobilization from the bone marrow was considered to improve outcome after ischemic stroke. Erythropoietin (EPO) might be a potential candidate stroke drug that increases the number of circulating EPCs. In the previous issue of Critical Care, Yip and colleagues investigated the effect of EPO in stroke patients on both clinical outcome and EPC stimulation. Although beneficial effects of EPO were observed, several issues regarding EPO's suitability as a stroke drug remain.
format Online
Article
Text
id pubmed-3219325
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-32193252012-03-09 Erythropoietin for stroke treatment: dead or alive? Minnerup, Jens Wersching, Heike Schäbitz, Wolf-Rüdiger Crit Care Commentary Endothelial progenitor cell (EPC) mobilization from the bone marrow was considered to improve outcome after ischemic stroke. Erythropoietin (EPO) might be a potential candidate stroke drug that increases the number of circulating EPCs. In the previous issue of Critical Care, Yip and colleagues investigated the effect of EPO in stroke patients on both clinical outcome and EPC stimulation. Although beneficial effects of EPO were observed, several issues regarding EPO's suitability as a stroke drug remain. BioMed Central 2011 2011-03-09 /pmc/articles/PMC3219325/ /pubmed/21418552 http://dx.doi.org/10.1186/cc10057 Text en Copyright ©2011 BioMed Central Ltd
spellingShingle Commentary
Minnerup, Jens
Wersching, Heike
Schäbitz, Wolf-Rüdiger
Erythropoietin for stroke treatment: dead or alive?
title Erythropoietin for stroke treatment: dead or alive?
title_full Erythropoietin for stroke treatment: dead or alive?
title_fullStr Erythropoietin for stroke treatment: dead or alive?
title_full_unstemmed Erythropoietin for stroke treatment: dead or alive?
title_short Erythropoietin for stroke treatment: dead or alive?
title_sort erythropoietin for stroke treatment: dead or alive?
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3219325/
https://www.ncbi.nlm.nih.gov/pubmed/21418552
http://dx.doi.org/10.1186/cc10057
work_keys_str_mv AT minnerupjens erythropoietinforstroketreatmentdeadoralive
AT werschingheike erythropoietinforstroketreatmentdeadoralive
AT schabitzwolfrudiger erythropoietinforstroketreatmentdeadoralive

Ejemplares similares